Search | Clinical Trials Finder

Conditions: Eustachian Tube Dysfunction
Interventions: Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray, Placebo Nasal Spray; Drug · Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Los Angeles, California • Sacramento, California • Indianapolis, Indiana + 1 more

Conditions: Chronic Sinusitis With or Without Nasal Polyps
Interventions: Fluticasone Propionate; Drug
Lead sponsor: Optinose US Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 705 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 18
States / cities: Phoenix, Arizona • Colorado Springs, Colorado • Largo, Florida + 15 more

Conditions: Asthma
Interventions: Fluticasone Furoate, Fluticasone Propionate, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 37
States / cities: Little Rock, Arkansas • Costa Mesa, California • Huntington Beach, California + 33 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Fluticasone Propionate/Salmeterol DISKUS 250/50mcg, Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 16
States / cities: Jasper, Alabama • Mobile, Alabama • Lafayette, Louisiana + 13 more

Conditions: Asthma
Interventions: Fluticasone Furoate/Vilanterol Inhalation Powder, Fluticasone Furoate Inhalation Powder, Fluticasone Propionate Inhalation Powder, Placebo Inhalation Powder 1, Placebo Inhalation Powder 2; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 23
States / cities: Bell Gardens, California • Huntington Beach, California • Long Beach, California + 19 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Trelegy Ellipta, Stiolto Respimat, Tiotropium + Olodaterol (5/5 mcg), Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg); Device · Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 9,117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: White Plains, New York

Conditions: Rhinitis, Allergic, Perennial
Interventions: FPNS, FFNS, placebo FFNS, placebo FPNS; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 20 more

Conditions: Bronchospasm, Activity/Exercise Induced Bronchospasm
Interventions: Fluticasone propionate/salmeterol, Fluticasone Propionate; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 50
States / cities: Little Rock, Arkansas • Huntington Beach, California • Orange, California + 45 more

Conditions: Eosinophilic Esophagitis
Interventions: APT-1011, Placebo oral tablet; Drug
Lead sponsor: Ellodi Pharmaceuticals, LP; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Indianapolis, Indiana • Boston, Massachusetts

Conditions: Asthma
Interventions: fluticasone/salmeterol 250/50 Dry Powder Inhaler, fluticasone/salmeterol 100/50 Dry Powder Inhaler, fluticasone 100mcg Dry Powder Inhaler; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 12 Years to 17 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 5
States / cities: Wilmington, Delaware • Jacksonville, Florida • Orlando, Florida + 2 more

Conditions: Asthma
Interventions: fluticasone, montelukast, Fluticasone plus salmeterol; Drug
Lead sponsor: JHSPH Center for Clinical Trials; Other
Eligibility: 6 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 19
States / cities: Birmingham, Alabama • Denver, Colorado • Jacksonville, Florida + 16 more

Conditions: Asthma
Interventions: fluticasone propionate/salmeterol, fluticasone propionate, placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Asthma
Interventions: Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler, Placebo inhalation powders via ELLIPTA inhaler, Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler, Placebo inhalation powder via ACCUHALER/DISKUS inhaler, Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 1,526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 34
States / cities: Huntington Beach, California • Riverside, California • Rolling Hills Estates, California + 30 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: ELLIPTA, DISKUS; Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 17
States / cities: Jasper, Alabama • Riverside, California • Clearwater, Florida + 14 more

Conditions: Asthma
Interventions: Mometasone, Advair; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bronchospasm, Activity/Exercise Induced Bronchospasm
Interventions: Fluticasone propionate/salmeterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 51
States / cities: Jonesboro, Arkansas • East Artesia, California • Huntington Beach, California + 45 more

Conditions: Nasal Polyps
Interventions: Fluticasone Propionate; Drug
Lead sponsor: Optinose US Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 16
States / cities: Birmingham, Alabama • Brandon, Florida • Normal, Illinois + 13 more

Conditions: Asthma
Interventions: Fluticasone Furoate/GW642444, Fluticasone furoate; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 2,020 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 64
States / cities: Birmingham, Alabama • Mobile, Alabama • Oxford, Alabama + 58 more

Conditions: Asthma
Interventions: FF/GSK573719, FF, FF/VI; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: St Louis, Missouri • Medford, Oregon • Orangeburg, South Carolina + 1 more

Conditions: Eosinophilic Esophagitis, Dysphagia
Interventions: Montelukast, Fluticasone; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Milwaukee, Wisconsin

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium, Olodaterol, Fluticasone propionate, Salmeterol; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 45
States / cities: Jasper, Alabama • Flagstaff, Arizona • Fullerton, California + 40 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Fluticasone Furoate/Vilanterol, Vilanterol, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 33 more

Conditions: Asthma
Interventions: Fluticasone / Salmeterol, Placebo, Advair Diskus 100/50; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 12 Years and older
Enrollment: 1,430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 100
States / cities: Glendale, Arizona • Phoenix, Arizona • Surprise, Arizona + 75 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF, VI, UMEC, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 13
States / cities: Jasper, Alabama • Clearwater, Florida • Tampa, Florida + 10 more

Search by objective public record fields.

Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD)

Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps

A Dose-ranging Study of Fluticasone Furoate (FF)

Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)

Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)

Comparator Study Evaluating Patient Experience And Preference Of FFNS vs. FPNS

A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise

Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial

Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial

The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial

Study Of RV-39 In Patients Who Also Have Asthma

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma

DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)

A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma

A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise

12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device

Asthma Exacerbation Study

Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma

Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone

The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)